Table 1.
siRNA | ASO | |
---|---|---|
Structure | Double-stranded RNA + two 3’ end overhanging nucleotides | Single-stranded DNA + flanking by modified RNA-like segments (gapmer) |
Ideal length | 21 nucleotides | 15–25 nucleotides |
Cellular entry | Requires conjugation to carrier for hepatocyte uptake | Can be taken into hepatocytes in unconjugated form |
Accumulation | In endosomes | In cytoplasm |
Dosing frequency | Less frequent (monthly) | More frequent (weekly or biweekly) |
Target mRNA binding | Requires RISC formation | Can bind to target alone |
Primary gene silencing mechanism | Target RNA cleavage by Argonaute | Target RNA cleavage by RNAse-H |
siRNA, small-interfering RNA; ASO, antisense oligonucleotide; mRNA, messenger RNA; RISC, RNA-induced silencing complex.